Ami Organics Ltd. Stock Analysis AMIORG.NS

Ami Organics Ltd. engages in the development and commercialization of pharmaceutical intermediate products and specialty chemicals. The company is headquartered in Surat, Gujarat and currently employs 676 full-time employees. The company went IPO on 2021-09-14. The firm is focused on the development and manufacturing of advanced pharmaceutical intermediates (Pharma Intermediates), New Chemical Entities (NCE) and other specialty chemicals for pharmaceuticals, agrochemicals, dyes, polymers, personal care, animal food, and other Industries. The company manufactures pharma intermediates for certain active pharmaceutical ingredient (APIs), including dolutegravir, trazodone, entacapone, nintedanib, and rivaroxaban. The pharma intermediates cater to several therapeutic areas, including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant. The firm has developed and commercialized over 520 plus products including specialty chemicals, Pharma Intermediates for APIs across 23 key therapeutic areas since inception and NCE across select high-growth high margin chronic therapeutic areas.